Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse events In comparison to placebo, treatment with REC-994 400 mg showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback